ADMA Biologics Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, ADMA Biologics stock has a consensus rating of "Buy" and an average price target of $17.6. The average 1-year stock price forecast is 111.79% higher than the current stock price, while the lowest is $12 (+44.40%) and the highest is $21 (+152.71%).

Price Target: $17.6 (+111.79%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$12	$17.6	$18	$21
Change	+44.40%	+111.79%	+116.61%	+152.71%

Analyst Ratings

The average analyst rating for ADMA Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	3	3	2	3	3	3
Buy	0	0	0	0	0	1
Hold	0	0	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	4	4	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ryan Deschner Raymond James	Raymond James	Buy Initiates $21	Buy	Initiates	$21	+152.71%	Jun 10, 2026
Anthony Petrone Mizuho Securities	Mizuho Securities	Buy Maintains $24 → $20	Buy	Maintains	$24 → $20	+140.67%	May 7, 2026
Gary Nachman Canaccord Genuity	Canaccord Genuity	Buy Maintains $18	Buy	Maintains	$18	+116.61%	May 5, 2026
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Hold Downgrades $30	Hold	Downgrades	$30	+261.01%	Mar 25, 2026

Financial Forecast

Revenue This Year

534.90M

from 510.17M

4.85%

from 510.17M

Revenue Next Year

701.11M

from 534.90M

31.07%

from 534.90M

EPS This Year

0.81

from 0.66

23.85%

from 0.66

EPS Next Year

1.00

from 0.81

22.64%

from 0.81

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	80.94M	154.08M	258.22M	426.45M	510.17M	534.90M
Revenue Growth	91.72%	90.36%	67.59%	65.16%	19.63%	4.85%
Gross Profit	1.17M	35.27M	88.94M	219.55M	292.77M	373.18M
Gross Margin	1.45%	22.89%	34.44%	51.48%	57.39%	69.77%
Operating Income	-57.57M	-39.37M	22.33M	138.98M	191.44M	251.18M
Net Income	-71.65M	-65.90M	-28.24M	197.67M	146.93M	197.45M
EPS	-	-	-	-	0.66	0.81
EPS Growth	-	-	-	-	34.05%	23.85%
Forward PE	-	-	36.16	25.28	22.24	10.22
Free Cash Flow	-96.39M	-53.50M	-934.38K	75.16M	-18.15M	136.70M
No. Analysts	-	-	-	-	-	3

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	540.1M
Avg	534.9M
Low	529.9M

Revenue Growth

Revenue Growth	2026	2027	2028
High	5.9%
Avg	4.8%
Low	3.9%

EPS Forecast

EPS	2026	2027	2028
High	0.83
Avg	0.81
Low	0.78

EPS Growth

EPS Growth	2026	2027	2028
High	26.4%
Avg	23.9%
Low	18.8%